Zinaura Pharmaceuticals
Zinaura PharmaceuticalsImproving the lives of patients by addressing profound unmet need in epilepsy and pain via development of HupA
Members:
Drew Cronin-Fine; Heather Kline
|
Industry Focus:
Life Sciences/Healthcare
Contact:
|
About
Zinaura is dedicated to improving the lives of epilepsy and pain patients through the clinical development of Huperzine A, a compound with blockbuster potential and a proven human safety profile. HupA has shown efficacy in rodent epilepsy and pain models; its novel mechanism of action in epilepsy has the potential to address the 30% of epilepsy patients who are unresponsive to current drugs. HupA is non-addicting, non-sedating, and does not impair cognition like many epilepsy and pain drugs.
(73 votes)
@zinaurapharma
-
Officially moved-in to @masschallenge and Cambridge Innovation Center for the summer. Amazing spaces and inspiring groups of people!
-
Zinaura has been chosen as a MassChallenge finalist: bit.ly/lPBxKM!! Thanks to those who voted! bit.ly/iOfe8M #masschallenge
-
Thanks for the great writeup on Zinaura and the other #mit100k finalists, @Xconomy! bit.ly/jelf1w
-
Zinaura was just selected for round 2 of #masschallenge! We pitch next week, thanks to everyone who voted! Standby for #MIT100K results!
